EYPT logo

EYPT
EyePoint Pharmaceuticals Inc

8,728
Mkt Cap
$1.08B
Volume
885,125.00
52W High
$19.11
52W Low
$3.91
PE Ratio
-4.12
EYPT Fundamentals
Price
$13.02
Prev Close
$12.89
Open
$13.08
50D MA
$14.57
Beta
1.24
Avg. Volume
1.3M
EPS (Annual)
-$3.17
P/B
3.52
Rev/Employee
$146,593.46
$1,055.00
Loading...
Loading...
News
all
press releases
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) CEO Jay Duker acquired 1,500 shares of Eyepoint Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were...
MarketBeat·16d ago
News Placeholder
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT
Rosalind Advisors Inc. acquired a new position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC...
MarketBeat·20d ago
News Placeholder
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...
MarketBeat·20d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.1% - Here's Why
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.1% - Should You Sell...
MarketBeat·21d ago
News Placeholder
Citigroup Boosts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $35.00
Citigroup lifted their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Monday...
MarketBeat·24d ago
News Placeholder
What is HC Wainwright's Estimate for EYPT Q1 Earnings?
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Research analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Eyepoint Pharmaceuticals in a research report issued...
MarketBeat·24d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·28d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00
HC Wainwright boosted their target price on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday...
MarketBeat·28d ago
News Placeholder
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
Chardan Capital raised their target price on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·28d ago
<
1
2
...
>

Latest EYPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.